Idexx Laboratories (IDXX) EBIT (2009 - 2026)

Idexx Laboratories' EBIT history runs 18 years deep, the most recent figure standing at $362.6 million for Q1 2026.

• In Q1 2026, EBIT rose 14.55% year-over-year to $362.6 million; the TTM figure through Mar 2026 stood at $1.4 billion (up 22.7% YoY), while the FY2025 annual figure was $1.4 billion, up 20.53% from the prior year.
• EBIT was $362.6 million for Q1 2026 at Idexx Laboratories, up from $315.6 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $373.0 million in Q2 2025 to a low of $179.1 million in Q2 2022.
• Historically, EBIT has averaged $285.1 million across 5 years, with a median of $280.4 million in 2023.
• The sharpest annual moves came in 2022 and 2023: EBIT plunged 30.93% in 2022, then jumped 65.38% in 2023.
• A 5-year view of EBIT shows it stood at $226.5 million in 2022, then grew by 8.29% to $245.3 million in 2023, then gained by 6.68% to $261.7 million in 2024, then climbed by 20.6% to $315.6 million in 2025, then grew by 14.89% to $362.6 million in 2026.
• The last three EBIT figures came in at $362.6 million (Q1 2026), $315.6 million (Q4 2025), and $354.8 million (Q3 2025), per Business Quant data.